secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001104659-25-074514
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel announces publication of non-clinical study on dexmedetomidine in Frontiers in Pharmacology
--------------------------------------------------------------------------------

- Study shows dexmedetomidine potently and reversibly regulates stress-mediated behaviors.
- Dexmedetomidine exhibited higher in vitro potency than clonidine, lofexidine, or guanfacine.
- Mitigated responses to acute and repeated stress after both acute and repeated dosing, with no loss of effect.
- No withdrawal effects; no impact on motor function or cognition vs. diazepam or scopolamine.
- Results support BXCL-501's potential for stress-related disorders beyond acute agitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/0001104659-25-074514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/tm2522638d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer